CCPR completes new specialty behavioral health provider network Comprehensive Care Corporation , which gives behavioral health, material at-risk and abuse psychotropic pharmacy management solutions for managed care businesses throughout the U.S. And Puerto Rico, is very happy to announce that CompCare de Puerto Rico provides completed its build out of a completely contracted and credentialed specialty behavioral wellness provider network to better serve its customers and covered Medicare and dual-eligible members across the Island of Puerto Rico.Combined, these results enhance airway hydration and assist in clearing mucus. The drug is different from other CF medications, which mainly treat the symptoms rather than the underlying causes, said Dr. Accurso, who’s also the director of University of Colorado’s cystic fibrosis center. This scholarly study may be the first large, stage 3 trial of an ion channel regulator in cystic fibrosis individuals with little if any baseline pulmonary function impairment. Accurso noted. Although available drugs target these problems, denufosol was made to deal with the underlying defects that cause the complications, and could modify the course of the disease potentially, particularly if administered early in the condition process. Experts enrolled 352 cystic fibrosis patients 5 years or older, and enrolled them to receive either inhaled denufosol or placebo three times daily for 24 weeks, followed by a 24-week open-label period when all individuals received denufosol.